0      0

LVSpecial - Independent CE-Accredited Satellite Symposium | Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors

‐ Nov 9, 2023 4:00pm

Click here to register now!

Supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

Key Reasons to Attend:

  • Better understand the rationale for using ADCs, as well as their unique mechanisms of action, efficacy and safety profiles, and evolving evidence supporting their use in different solid tumors
  • Improve your identification of patients with different tumor types who may benefit from ADCs in clinical practice and clinical trials
  • Learn how to integrate HER2-, HER3-, and TROP2-targeting ADCs into treatment plans for patients with different solid tumors according to the latest evidence and expert recommendations, and effectively manage different AEs associated with these agents